WOS

Permanent URI for this collectionhttps://hdl.handle.net/11443/932

Browse

Filters

20211

Settings

Author: search.filters.author.Albayrak, CananSubject: search.filters.subject.Children

Search Results

Now showing 1 - 1 of 1
  • No Thumbnail Available
    Item
    Different Kinetics and Risk Factors for Isolated Extramedullary Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Acute Leukemia
    (ELSEVIER SCIENCE INC, 2021-01-01) Hazar, Volkan; Ozturk, Gulyuz; Yalcin, Koray; Uygun, Vedat; Aksoylar, Serap; Kupesiz, A.; Bozkaya, Ikbal Ok; Karagun, Barbaros Sahin; Bozkurt, Ceyhun; Ileri, Talia; Atay, Didem; Kocak, Ulker; Karasu, Gulsun Tezcan; Yesilipek, Akif; Gokce, Muge; Kansoy, Savas; Kintrup, Gulen Tuysuz; Karakukcu, Musa; Okur, Fatma Visal; Ertem, Mehmet; Kaya, Zuhre; Gursel, Orhan; Yaman, Yontem; Ozbek, Namik; Antmen, Bulent; Tufekci, Ozlem; Albayrak, Canan; Aksoy, Basak Adakli; Sezgin, Gulay; Albayrak, Davut; Evim, Melike Sezgin; Zengin, Emine; Pekpak, Esra; Transpl, Turkish Pediat Bone Marrow
    Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the most frequent cause of post-transplantation mortality. Isolated extramedullary (EM) relapse (iEMR) after HSCT is relatively rare and not well characterized, particularly in pediatric patients. We retrospectively analyzed 1527 consecutive pediatric patients with acute leukemia after allo-HSCT to study the incidence, risk factors, and outcome of iEMR compared with systemic relapse. The 5 -year cumulative incidence of systemic relapse (either bone marrow {[}BM] only or BM combined with EMR) was 24.8\%, and that of iEMR was 5.5\%. The onset of relapse after allo-HSCT was significantly longer in EM sites than in BM sites (7.19 and 5.58 months, respectively